One biotech startup wants to restore vision in blind patients with a gene therapy that gives light sensitivity to neurons that don't normally possess it.
The attempt, by Ann Arbor, Michigan-based Retrosense Therapeutics, will use so-called optogenetics. Scientists have used the technique over the last few years as a research tool to study brain circuits and the neural control of behavior by directing neuron activity with flashes of light. But Retrosense and others groups are pushing to bring the technique to patients in clinical trials.
To read the full, original article click on this link: Company Aims to Cure Blindness with Optogenetics - Technology Review
